Jun 26 |
Repare Therapeutics Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRI
|
Jun 10 |
Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of TRESR Clinical Trial
|
Jun 6 |
Repare (RPTX) Up 14% as Ovarian Cancer Combo Gets Fast Track Tag
|
Jun 4 |
Repare gets FDA fast track status for ovarian cancer drug combo
|
Jun 4 |
Repare Therapeutics Announces Fast Track Designation Granted by the FDA for Lunresertib in Combination with Camonsertib for the Treatment of Platinum-Resistant Ovarian Cancer
|
Jun 3 |
Repare Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
|
May 29 |
Repare Therapeutics to Present Initial Phase 1 MINOTAUR Data at ESMO GI Congress 2024
|
May 12 |
Need To Know: Analysts Are Much More Bullish On Repare Therapeutics Inc. (NASDAQ:RPTX)
|
May 9 |
Repare Therapeutics First Quarter 2024 Earnings: Beats Expectations
|
May 7 |
Repare Therapeutics GAAP EPS of $0.30 beats by $0.32, revenue of $52.4M beats by $14M
|